Rating: Cautiously Bullish | Target Price: RMB 27.5–30.4 (base-case fair value range, midpoint RMB 29.0) Current Price: RMB 26.15 (2026-10-27 close, frozen price anchor) | Margin of Safety: ~+5.2% (base-case fair value floor RMB 27.5 vs. current price) Time Horizon: 6–12 months | Market cap RMB 45.86 billion (1.7537 billion total shares) | PE(TTM) ~13.3x, PB ~1.80x (10-year low), TTM dividend yield ~3.56%
Huadong Medicine's current share price of RMB 26.15 (at the bottom of its 52-week range of RMB 26.00–43.65, -34% YTD) has already priced in most of the two major negatives: the loss of 4 products in the 12th national centralized procurement round (2025 sales of RMB 4.634 billion, accounting for 31.34% of pharmaceutical industrial revenue) and the accelerating decline in medical aesthetics revenue (-41.4% in 2026H1). The current price implies a perpetual growth rate of only ~1.5–1.7%, effectively assigning near-zero value to the GLP-1 pipeline and medical aesthetics recovery. Yet the company's true earnings foundation is solid: the industrial segment delivered RMB 3.355 billion in net profit in 2025 (+15.6%); innovative product revenue reached RMB 2.34 billion (+64.2%, another +52% in 2026H1); operating cash flow/net profit has exceeded 1 for four consecutive years; net cash stands at RMB 3.451 billion; and the dividend yield is 3.56% — displaying clear characteristics of a "bond-like holding plus free options." We judge this to be a shallow discount rather than deep mispricing: execution of the centralized procurement in 2027 will compress attributable net profit to a midpoint of ~RMB 3.33 billion (-7% vs. this report's 2026E of ~RMB 3.58 billion, a notably steeper decline than 2025's -2.78%), with a bear-case floor of RMB 19.4. On the upside, the oral GLP-1 drug HDM1002 has already met its Phase III primary endpoints, with NDA submission in 2026Q4; catalysts are dense from 2026Q4 through 2027Q1. Base-case fair value is RMB 27.5–30.4 (+5% to +16%), with a probability-weighted expected value of ~RMB 29.2 (+11.7%). Above-average quality, slightly below fair value — cautiously bullish, awaiting two-way validation from the Q3 report and procurement execution details.
The core of upcoming change: The company is in a transition gap, shifting from old growth drivers (procurement-exposed large-volume generics + Ellansé) to new ones (innovative drugs + GLP-1 metabolic pipeline). Three things from 2026Q4 onward will determine direction: ① provincial execution documents for the 12th procurement round and the actual magnitude of in-hospital revenue loss; ② HDM1002 weight-management NDA acceptance + Phase III diabetes data readout + HDM1005 dual-agonist head-to-head data (2026Q4 window); ③ whether the medical aesthetics decline narrows in the Q3/annual report.
Primary share price drivers: The next 6 months are both the pricing-confirmation period for procurement execution and the dense realization period for GLP-1 registration milestones. The two forces point in opposite directions but are of comparable magnitude (procurement profit gap of ~RMB 500–650 million/year at midpoint vs. risk-adjusted value of HDM1002 of ~RMB 2.6–6.1 billion in one-time re-rating potential). Share price volatility will revolve around marginal information on these two forces.
Verifiable expectation gaps: Market consensus for FY2027 attributable net profit is ~RMB 3.76 billion (implying ≤RMB 200 million procurement profit impact + a fairly quick medical aesthetics recovery); we estimate a midpoint of RMB 3.33 billion (~55% in-hospital attrition, ~25% out-of-hospital recapture), about 11% below the Street — the disagreement is quantitative, not directional. The contrarian expectation gap: if the indobufen crystal-form patent enforcement succeeds and out-of-hospital recapture exceeds expectations, the 2027 decline will be materially smaller than both our and the market's pessimistic estimates.
Catalysts for validation and falsification: See Chapter VII tracking arrangements (Q3 report around 2026-10-31, HDM1002 NDA acceptance, procurement execution documents, 2026 annual report goodwill impairment test). Evidence grade B: core financials and announcement originals are verifiable, but three key inputs — procurement execution details, patent litigation outcomes, and the timing of HDM1002 approval — lack definitive documents.
Per the company's 2026-08-03 announcement: indobufen tablets, isavuconazonium injection, pioglitazone/metformin tablets, and alogliptin benzoate tablets were not selected, with combined 2025 sales of ~RMB 4.634 billion (10.62% of revenue, 31.34% of pharmaceutical industrial revenue including CSO); the four products generated RMB 1.348 billion in 2026Q1 alone (share rising to 33.30%, base still expanding); the procurement cycle runs from execution to 2029-12-31, with in-hospital volumes under guaranteed procurement certain to be lost. Adding the 3 products拟中选/selected (ciclosporin, tacrolimus, mesalazine, combined 2025 sales of RMB 2.076 billion) trading price for volume, this report estimates a total 2027 procurement profit gap of ~RMB 310–860 million (midpoint ~RMB 500–650 million). Innovative product increments (+RMB 290–350 million) can only partially offset this; 2027 attributable net profit is projected at RMB 2.83–3.78 billion, midpoint ~RMB 3.33 billion — about -2.5% vs. the actual 2025 figure of RMB 3.414 billion, and about -7% vs. this report's 2026E (~RMB 3.58 billion, annualized from 2026H1 accounting for the pre-procurement H2 base). The company's attributable net profit already fell -2.78% YoY in 2025; 2027 will see a significantly deepening decline, not a "first-time drop."
Key upside variable: indobufen has built a crystal-form patent barrier (administrative rulings and lawsuits filed against 15 infringing companies with "positive progress achieved"). If victorious and out-of-hospital recapture exceeds expectations, retention will exceed this report's 35% midpoint assumption; conversely, patent invalidation would open the downside scenario. The specific terms of provincial execution documents (execution start date, listing price restrictions, usage space beyond guaranteed volumes) are the largest unresolved input.
Medical aesthetics segment revenue peaked at RMB 2.447 billion in 2023 (+27.79%, a historical best), then declined for two consecutive years with widening drops: ~RMB 2.326 billion in 2024 (~-4.9%), RMB 1.826 billion in 2025 (-21.50%, of which overseas Sinclair RMB 958 million at only -0.95% and domestic Sinclair China (欣可丽) RMB 780 million at -31.50%), and only RMB 651 million in 2026H1 (-41.43%, domestic -52.46%, overseas -36.59%). The domestic decline stems mainly from a supply explosion in regenerative injectables (46 Class III injectable medical aesthetics products approved by NMPA from 2025-07 to 2026-06; industry observation, pending verification), eroding Ellansé's first-mover premium and triggering terminal price wars; overseas weakness became explicit in 2026H1 (channel and organizational restructuring, soft European consumption). The Sinclair cash-generating unit's goodwill impairment test (2026-06-30) has an extremely thin safety buffer: carrying value RMB 2.682 billion vs. recoverable amount RMB 2.741 billion, a buffer of only ~RMB 59 million (2.2%), and the test's forecast-period revenue growth assumptions (+1.49% to +21.87%) clearly diverge from the actual -36.6% trend. If the overseas trend persists, the 2026 annual report faces further impairment risk (this report's stress estimates: moderate RMB 200–400 million, severe RMB 500–800 million).
Management targets "medical aesthetics performance in H2 2026 better than H1, and 2027 better than 2026"; 4 new products (Ruituoxin recombinant type A botulinum toxin, Yinyan Yishen Hengyao, V30 device, MaiLi Precise) have been approved. If the medical aesthetics single-quarter decline narrows to within -20% by 2026Q4, the "falsification" narrative would need partial reversal — the key contrarian checkpoint for C2.
HDM1002 (oral small-molecule GLP-1 receptor agonist) met all primary endpoints in its weight-management Phase III: 44-week weight reduction of 9.2%/10.7% at 200mg/400mg, and 12.2% at 52 weeks with no plateau observed; Pre-NDA communication is complete, with NDA submission in 2026Q4 — among the first tier of domestic oral GLP-1 weight-management filings. The demand-side inflection is supported by hard numbers: ~180 million obese and ~377 million overweight adults in China (NHC figures); 2025 weight-management GLP-1 sales through regulated channels were only ~RMB 900 million (Wegovy's first full year, penetration <0.1%). At 180 million people × RMB 12,000/year × penetration, a 3% penetration rate in 2030 ≈ a RMB 64.9 billion market — volume precedents exist (Innovent's mazdutide generated ~RMB 720 million in its first year post-approval, with institutional estimates of RMB 1.8 billion for 2026). This report discounts HDM1002 at peak revenue of RMB 1–2 billion × 25% net margin × 15–20x exit PE × 50–70% probability of realization, yielding a risk-adjusted value of ~RMB 2.6–6.1 billion. Price-action review shows that on the topline announcement day (2026-09-28) the stock closed at RMB 27.02, up only +3.7% (~RMB 1.7 billion in market cap) from the pre-announcement close (09-24: RMB 26.06), and fell back within a month — the market underprices this pipeline but does not price it at zero. Risks are equally concrete: Eli Lilly's orforglipron (~-12.4% at 40 weeks, slightly better data) is FDA-approved, filed in China, and could win Chinese approval as early as within 2026; 11+ domestic semaglutide biosimilars are queued (trial data protection running to roughly 2027-04); HDM1002 faces a 1–2 year lag in approval timing, and if oral GLP-1 launches into an annual-price war below RMB 3,000, peak revenue assumptions face downward revision.
The group's profit ballast is pharmaceutical industrials: in 2025 the segment contributed RMB 3.355 billion in attributable net profit (+15.59%), ~87.5% of group segment profit; innovative product revenue was RMB 2.34 billion (+64.2%), reaching RMB 1.684 billion in 2026H1 (+52%), 21.14% of industrial revenue. Earnings quality: OCF/attributable net profit was 1.38 / 1.07 / 1.24 for 2023–2025 and 1.34 in 2026H1 (2024's dip just below 1.2 reflects normal fluctuation in pharma commercial receivables); net cash of RMB 3.451 billion and a debt-to-asset ratio of 35.51% at 2026-06-30; TTM dividend of RMB 0.93/share (2025 annual RMB 5.8 per 10 shares + 2026 interim RMB 3.5 per 10 shares), yield ~3.56%; cumulative dividends since listing of RMB 9.89 billion with no dilutive equity issuance. Valuation percentiles: PE(TTM) ~13.3x (~1st percentile over 5 years), PB ~1.80x (10-year low); this report's zero-growth EPV (equity free cash flow basis) is ~RMB 14.7–22.1/share, midpoint RMB 18.0, covering ~69% of the current price. Restraints to retain: on the 2027E midpoint of RMB 3.33 billion, the current price implies a forward PE of ~13.8x, above the TTM basis; and with procurement normalization, the industrial segment's valuation anchor has systematically shifted lower, weakening comparability with its own historical percentiles — the solidity of the valuation floor ultimately depends on the procurement impact being no worse than the midpoint assumption.
| Metric | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Operating revenue | 406.24 | 419.06 | 436.12 | 220.67 (+1.81%) |
| Attributable net profit | 28.39 | 35.12 | 34.14 | 18.61 (+2.53%) |
| Non-GAAP attributable net profit | 27.37 | 33.52 | 33.11 | 18.58 (+5.44%) |
| Overall gross margin | 32.40% | 33.21% | 32.36% | 32.80% (-1.10pp) |
| Attributable net margin | 6.99% | 8.38% | 7.83% | 8.43% |
| Net operating cash flow | 39.29 | 37.49 | 42.46 | 24.99 (+1.73%) |
| Free cash flow (OCF−CapEx) | — | 20.21 | 26.72 | 17.81 |
| Cash (period-end) | 46.63 | 52.76 | 49.78 | 56.05 |
| Interest-bearing debt (period-end) | 17.59 | 27.29 | 20.72 | 21.54 |
| Net cash (period-end) | 29.04 | 25.47 | 29.06 | 34.51 |
| Debt-to-asset ratio | — | 37.79% | 35.52% | 35.51% |
| R&D expense (expensed) | — | 14.26 | 17.53 | 7.47 (-25.27%) |
Note: Balance-sheet stock figures are uniformly taken from each period's period-end balance sheet; "latest period" is 2026-06-30; free cash flow is this report's estimate on an OCF − CapEx (fixed assets, etc.) basis (the company does not disclose a self-defined FCF); FY2023 non-GAAP figure is back-calculated from the annual report's non-recurring items table. Pharmaceutical industrials are the net profit core and the company is in a net cash position (negative net debt), so net debt/EBITDA is not applicable.
Reasons for metric changes (YoY ≥ ±20% excerpts, all with company explanations): ① Medical aesthetics segment revenue -21.50% in 2025 → -41.43% in 2026H1 (domestic -52.46%): the company attributes this to "deep industry adjustment, intensifying competition, price involution, and the phased growing pains of its own strategic adjustment and upgrade"; ② 2026H1 R&D expense -25.27%: at the results briefing the company explained this as capitalization of development spend as GLP-1, ADC and other pipelines entered Phase III, plus a high base from prior-year license-in milestone payments, stating "actual funding input has not been materially reduced"; ③ 2025 capitalized R&D investment +110.6% to RMB 752 million, capitalization ratio rising from 20.18% to 30.43%: company IR explains this as Phase III pivotal clinical capitalization (the annual report marked this item "not applicable" without specific explanation); ④ Innovative product revenue +64.2% in 2025 and +52% in 2026H1: volume ramp-up of innovative drugs and new improved formulations (ustekinumab sales of RMB 300+ million in 2026H1, +100%); ⑤ 2025 investment income of -RMB 138 million: ~RMB 140 million combined impact from equity-method operating losses of overseas associates Heidelberg Pharma and R2; ⑥ 2025 net financing cash outflow of RMB 2.822 billion: annual dividends of RMB 1.631 billion + debt repayment of RMB 3.523 billion.
2026H1 revenue of RMB 22.067 billion (+1.81%), attributable net profit RMB 1.861 billion (+2.53%), non-GAAP RMB 1.858 billion (+5.44%). Against consensus FY2026 attributable net profit of ~RMB 3.65 billion, H1 completion was ~51%, broadly in line with the 2025 H1 share (53%) — no earnings event of an earnings beat or miss. Structurally, the divergence of "strong industrials, weak medical aesthetics" has widened: pharmaceutical industrials continued mid-to-high single-digit growth (innovative products +52%, ustekinumab doubling), while medical aesthetics fell -41.4%, dragging revenue by ~RMB 460 million. Gross margin of 32.80% (-1.10pp) was mainly due to the shrinking share of high-margin medical aesthetics and price pressure on legacy industrial products. The "respectable" +2.53% profit growth had an accounting contribution: expensed R&D fell -25.27% YoY (a RMB 253 million difference); normalized to the prior year's expensed level, H1 profit growth would be roughly flat — a presentation sensitivity this report highlights in its earnings quality section. Cash flow remained excellent (OCF RMB 2.499 billion, OCF/net profit of 1.34), with net cash rising to RMB 3.451 billion. Management gave no quantitative guidance, only qualitatively stating "H2 medical aesthetics better than H1, 2027 better than 2026."
Business model snapshot: The group is a composite of "one high-margin industrial business + one large-scale, low-margin distribution business + two incubating businesses" — pharmaceutical manufacturing (Sino-US Huadong, prescription drug manufacturing, 2025 revenue RMB 14.784 billion, segment net profit attributable to parent RMB 3.355 billion) is the sole profit engine; pharmaceutical distribution (Zhejiang provincial distribution leader, revenue RMB 29.449 billion, net profit only RMB 479 million, net margin ~1.7%) is essentially a channel services business providing scale, cash flow, and in-hospital channel synergies; medical aesthetics (Sinclair + Sinclair China) and industrial microbiology (synthetic biology platform) are the second and third growth curves in consumer healthcare and B2B. Revenue is highly recurring (chronic disease medications and distribution are both repeat-purchase businesses), but pricing power in industrial prescription drugs remains persistently suppressed by centralized procurement (VBP); innovative drugs and licensed medical aesthetics products are the parts with genuine pricing power.
Cash content of earnings: OCF/net profit attributable to parent was 1.38 / 1.07 / 1.24 in 2023–2025 and 1.34 in 2026H1 — consistently above 1, meaning book profits largely convert to cash. FCF/net profit attributable to parent was 0.58 in 2024, 0.78 in 2025, and ~0.96 (annualized) in 2026H1, improving steadily as capex declines. Recurring earnings test: In 2025, non-GAAP recurring net profit of RMB 3.311 billion differed from net profit attributable to parent of RMB 3.414 billion by only ~3% (non-recurring items ~RMB 100 million) — core earnings were not dressed up by one-off items. However, two caveats on reporting caliber deserve reverse scrutiny: the company's self-reported "core recurring profit excluding share-based compensation expenses and equity-method results of invested/controlled R&D institutions" (RMB 3.709 billion in 2024) was ~10.7% higher than statutory recurring profit; the excluded share-based compensation is a recurring annual expense, making this an overly generous caliber. Meanwhile, in 2026H1, expensed R&D fell -25.3% while the capitalization ratio jumped to ~32.7% (RMB 362 million / RMB 1.109 billion of R&D investment); after adjusting for this, H1 profit growth was close to zero.
Return on capital: This report estimates 2025 ROIC at ~12.8% (NOPAT/(net assets + interest-bearing debt)), ~4 percentage points above estimated WACC (~8–9%), with ROE ≥14% for four consecutive years — in the "genuine moat but not top-tier" range. The moat comes from cost advantages of fermentation-based API-to-formulation integration and the Zhejiang distribution network, not from single-point technological leadership.
Capex quality: 2025 CapEx of RMB 1.574 billion / D&A of RMB 1.040 billion ≈ 1.51, including growth investments such as the Biological Innovation & Smart Manufacturing Center; the company does not disclose a maintenance vs. growth split, so the maintenance investment level cannot be determined. Development expenditures (capitalized R&D) balance of RMB 2.120 billion (end of 2026H1) is essentially another "R&D capex" line, whose returns depend on pipeline delivery.
Red flags: ① Equity-method losses from overseas associates (Heidelberg Pharma, R2) dragged 2025 by ~RMB 140 million — a recurring drag (turned positive +RMB 28 million in 2026H1); ② The medical aesthetics segment has been contracting continuously, and the impairment-testing cushion on goodwill of RMB 2.860 billion (7.3% of total assets) is extremely thin; ③ The jump in the R&D capitalization ratio from 20.18% → 30.43% directly boosted current-period profit by roughly RMB 200–240 million. Top-five customer concentration was 22.68%, largest customer 8.84% — concentration is manageable.
Track record of words vs. actions: partially delivered, with a preference for qualitative statements. ① 2024 operating targets (deepening transformation across segments, expanding medical aesthetics market share) → 2024 net profit attributable to parent +23.72%, delivered; ② The 2024 annual report positioned 2025 medical aesthetics as "high-end market, multi-channel share expansion" → medical aesthetics -21.5% in 2025, -52% in 2026H1 — clearly not delivered; ③ The 2024 performance targets under the 2022 restricted stock incentive plan (recurring profit excluding share-based payment of RMB 3.709 billion, +35.52%) were claimed as achieved by the company, delivered; ④ The commitment to file an NDA for HDM1002 (weight loss) in 2026Q4: Pre-NDA completed in July 2026, topline results met in September — in progress and on track. Overall verdict: high project execution delivery rate (clinical and registration milestones essentially on schedule), but operating targets are never given quantitatively (revenue/profit targets have been qualitative year after year), making them unfalsifiable — the company twice declined to quantify VBP impact when questioned, a governance demerit.
Shareholder friendliness: shareholder-friendly. Payout ratio rose from 35.8% in 2023 → 46.4% in 2024 → 47.8% in 2025; the first-ever interim dividend was implemented in 2026 (RMB 3.5 per 10 shares, RMB 614 million, paid in September); cumulative dividends since listing total RMB 9.890 billion. No market-level buybacks (buyback-and-cancellation "under continuous evaluation"), no new share issues/rights issues/convertible bonds — zero dilution of total share capital. Responding to record-low share prices with an interim dividend is pragmatic but conservative market cap management.
Risk signals: Controlling shareholder China Grand Pharmaceutical & Healthcare Holdings holds 41.67%, of which 144.8 million shares are pledged (19.81% of its holdings, 8.26% of total share capital, as of 2026-06-30) — a moderate ratio with no margin-call risk signals; no increases/decreases in holdings in the past 12 months, no unlocking batches; board re-election in July 2025; no major related-party transactions disclosed; BD fulfillment flaw (supply delay to Yanduo; the company says it "does not rule out legal action").
| Segment | 2025 Revenue (RMB 100M) | Share | Gross Margin | YoY | One-Line Business Logic |
|---|---|---|---|---|---|
| Pharmaceutical Manufacturing (incl. CSO) | 147.84 | 33.90% | ~77.0% (manufacturing basis) | +7.04% | Innovative drugs + blockbuster generics; the group's sole profit engine |
| Pharmaceutical Distribution | 294.49 | 67.53% | 7.33% (down to 6.62% in 2026H1) | +3.44% | Zhejiang distribution leader; large scale, thin margins, stable cash flow |
| Medical Aesthetics (net of intercompany eliminations) | 18.26 | 4.19% | Not separately disclosed (overseas basis 53.76%) | -21.50% | Regenerative injectables + botulinum toxin + energy-based devices; in deep adjustment |
| Industrial Microbiology | 7.77 | 1.78% | Not disclosed | +9.34% | xRNA / ADC toxins / peptide synthetic biology platform |
Core profit segment: Pharmaceutical Manufacturing contributes RMB 3.355 billion in segment net profit on 33.9% of revenue (roughly 7x the distribution segment's RMB 479 million), accounting for ~87.5% of group segment profit — analyzing Huadong Medicine means analyzing Sino-US Huadong. Distribution is a revenue amplifier and channel synergy component, not a source of value. The gross margin structure gap (77% vs. 7.3%, ~70pp apart) stems from entirely different businesses: manufacturing is licensed prescription drug production (pricing power from patented/exclusive products), while distribution is a logistics service squeezed by VBP and DRG (earning logistics and working-capital fees). Medical aesthetics' revenue share has fallen to 2.95% (2026H1); its marginal impact on profit now takes a back seat to its goodwill risk.
Accounting red flags: ① Jump in R&D capitalization ratio (medium-high severity): 23.04% in 2023 → 20.18% in 2024 → 30.43% in 2025 (capitalized amount +110.6% to RMB 752 million), rising further to ~32.7% in 2026H1; development expenditure balance grew 1.03 → 1.76 → 2.12 billion. The "reasons for major changes in capitalization ratio" field in the annual report was checked "not applicable," with only a verbal earnings-call explanation that Phase III programs were capitalized — each 10pp increase in the capitalization ratio boosts pre-tax profit by roughly RMB 240 million; if the expensing pace rebounds in 2027, earnings will face a second round of pressure. ② Impairments concentrated in Q4 (medium): 2025Q4 standalone net profit attributable to parent of RMB 666 million (-28.6% QoQ), with goodwill impairment of RMB 78.11 million and non-operating expenses of RMB 126 million concentrated in Q4. ③ Self-reported Non-GAAP caliber overly generous (low): "core recurring profit" excluding share-based compensation and equity-method results of R&D institutions is ~10.7% above statutory recurring profit; share-based compensation is a recurring expense. ④ Inventory growth exceeding revenue growth (low): +15.9% at end-2025 vs. revenue +4.07%.
Cross-period consistency: ① The capitalization ratio series (23.04% → 20.18% → 30.43% → 32.7% in H1) alongside expensed R&D shifting from growth to decline — not explained in periodic reports (earnings-call statements only); ② The medical aesthetics growth series (+27.79% → -4.9% → -21.5% → -41.4%) shows progressively widening declines — consistent with management's explanations; ③ Effective tax rate 18.77% → 15.08% → 16.78% (2026H1), fluctuating nearly 4pp and boosting 2025 net profit — not explained by the company (common causes: R&D super-deductions and changes in high-tech enterprise structure).
Current market data and percentile (as of 2026-10-27 close, frozen anchor): Share price RMB 26.15, market cap RMB 45.86 billion; PE (TTM) 13.25x (≈4%/1%/1% percentiles over 1/3/5 years), PB 1.80x (0% percentile over 10 years, historical low), PS (TTM) ~1.04x (diluted by 67.5% low-margin distribution revenue; not comparable cross-sectionally); TTM dividend yield 3.56%. Average daily turnover ~RMB 300–500 million (~1% of market cap), normal liquidity. Percentile disclaimer: TTM earnings still include pre-VBP revenue; on the 2027E midpoint of RMB 3.33 billion, forward PE is ~13.8x — percentiles serve only as a "market sentiment gauge" and should not be the headline signal for cheapness or expensiveness.
Peer benchmarking (2026-10-27, PE on a mixed static/TTM basis):
Huadong trades at a ~30–38% discount to the peer median (~16–20x): ~17% discount to Sino Biopharmaceutical (the most directly comparable mixed generic-innovative play) and ~66% discount to Hengrui (innovative purity premium). The discount maps to slower innovation delivery plus two low-multiple assets (distribution and medical aesthetics) as drags — directionally justified; but the 10-year-low PB plus 3.56% dividend yield suggest the discount has reached historical extremes.
Market-implied expectations: Triple reverse-engineering — ① At a 9% cost of equity, PE of 13.3x implies perpetual growth of ~1.5–1.7%; even using 2027 post-VBP earnings of RMB 1.90/share as the base yields only ~1.7%: the market is pricing in near-zero growth post-VBP; ② SOTP back-calculation: RMB 45.86bn market cap − RMB 3.45bn net cash − ~RMB 4.8bn distribution (RMB 479M net profit × 10x) − ~RMB 1.0bn medical aesthetics − ~RMB 2.0bn industrial microbiology → manufacturing core at only ~RMB 34.6bn = 10.3x 2025 manufacturing net profit — the group's sole profit engine is valued as a "declining generics business," with GLP-1 and medical aesthetics recovery almost entirely unpriced (event study of topline announcement day +3.7% corroborates this underpricing); ③ Dividend yield of 3.56% with a 47.8% payout ratio — bond-like characteristics. In one sentence: at current prices, the market requires the manufacturing engine to grow perpetually at just 1.5% post-VBP, whereas reality shows manufacturing profit +15.6%, innovative products +64%, and a proven RMB 900M → RMB 1.8bn/year ramp precedent in the weight-loss drug space — the direction is justified, the magnitude is harsh, but 2027 earnings-downgrade risk is equally real.
Three-tier value (EPV): Equity basis; normalized net profit attributable to parent ~RMB 3.6 billion (2025 recurring 3.311 + goodwill impairment 0.78 + overseas equity-method losses 1.4; cross-checked against annualized 2026H1 recurring profit of RMB 3.716 billion), bridged to sustainable FCFE of ~RMB 2.85 billion (+ D&A 940 − maintenance CapEx ~900 − working capital increase ~250 − growth-related capitalized R&D ~550) = RMB 1.62/share; divided by 9% cost of equity (rf 1.8% + β0.9 × ERP 6% + risk premium for VBP/medical aesthetics/GLP-1 of ~1.8pp) gives EPV of ~RMB 18.0/share (range RMB 14.7–22.1, sensitive to ±100bp in cap rate), covering ~69% of the current price; the growth option (current price − EPV) is ~RMB 8.1, or ~31% of the current price — the premium the market pays for "GLP-1 + medical aesthetics recovery + innovation increments" is at a reasonable-but-low range, not a freebie. Asset value (floor) is ~RMB 12.9/share (book net assets excluding goodwill), before deducting the RMB 2.12 billion development expenditure (from a pipeline replacement-cost perspective, the floor can only be higher).
Three scenarios and odds:
| Scenario | Probability | Fair Range | Key Swing Factors | vs. Current Price |
|---|---|---|---|---|
| Bear | 25% | RMB 19.4–21.8 | In-hospital loss of delisted products ≈75%, out-of-hospital absorption <10%; medical aesthetics down another 20%+ in 2027 with further goodwill impairment; HDM1002 approval delayed to 2028+ → net profit ~RMB 2.83bn (-21%), at 12–13.5x (near its historical low of 11.4x) | -26% ~ -17% |
| Base | 50% | RMB 27.5–30.4 | In-hospital loss ≈55%, ~25pp recovered via out-of-hospital/non-medical institutions (profit -RMB 520M); medical aesthetics stabilizes; innovation +RMB 350M; HDM1002 approved in 2027H2 → net profit ~RMB 3.33bn, at 14.5–16x (anchor: 80–90% of Sino Biopharmaceutical's 16x, plus 75% of its own 3/5-year median, independent of the current price) | +5% ~ +16% |
| Bull | 25% | RMB 36.7–39.9 | VBP impact <35%; medical aesthetics turns +15–20% in 2027; HDM1002 approved with visible ramp (referencing mazdutide's RMB 700M → 1.8bn path) + semaglutide generic approved in 2027 → net profit ~RMB 3.78bn, at 17–18.5x (moving toward mid-single-digit-growth pricing after dual innovation+GLP-1 delivery, still far below Hengrui) | +40% ~ +53% |
The current price of RMB 26.15 sits between the bear and base cases, nearer the lower end. Probability-weighted expected price ~RMB 29.2 (+11.8%). External anchor check: UBS downgraded to Neutral on 2026-10-22 with a target of RMB 28 (12-month midpoint estimate, falling within our base-case range); sell-side mean RMB 39.04 / median RMB 42 (near our bull case) — the current price is even below the most bearish major broker's midpoint, with market pricing one notch more conservative than the sell side overall.
House earnings forecast (anchor for next earnings reconciliation):
| Period | Revenue (RMB 100M) | Net Profit Attr. (RMB 100M) | Key Drivers |
|---|---|---|---|
| FY2026E | 444–451 | 35.3–36.5 | Manufacturing +7~9% (innovation +50~60% to ~RMB 3.5bn); distribution +2~3%; medical aesthetics -30~35%; limited in-year VBP impact |
| FY2027E | 428–453 | 28.3–37.8 (midpoint 33.3) | Delisted 4 products profit gap -3.1~-8.6 hundred million; selected 3 products -0.6~-1.5 hundred million; medical aesthetics -0.5~+1.2 hundred million; innovation +2.9~3.5 hundred million; GLP-1 0~+1.2 hundred million |
Benchmark check: Consensus FY2026/2027 net profit ~RMB 3.65/3.76 billion — our 2026 estimate is broadly in line; 2027 is ~11% below the Street (Street implies VBP impact ≤RMB 200 million; we believe out-of-hospital absorption is overestimated). Consensus EPS over the past 90 days has been revised down -5.7%, converging toward our view.
Conclusion: modestly undervalued. Evaluate quality (ROE 14%, net cash, strong cash flow) and price (10-year-low PB, implied g of 1.5%) separately: the current price is slightly below the base-case fair value floor, with a safety margin of ~+5.2% (floor basis) — the odds are mildly positive but not a deep mispricing; a 2017-style "Davis Double Play" requires both better-than-neutral VBP execution and GLP-1 delivery to hold simultaneously.
Industry size. Huadong spans three sub-tracks with vastly different sizes and growth rates. ①Injectable medical aesthetics: China's medical aesthetics injectables retail market was approximately RMB 67.0 billion in 2023 (RMB 25.7 billion in 2018, per Frost & Sullivan), with a 2018–2023 CAGR of about 21.1%, projected to reach RMB 147.0 billion by 2027 (CAGR about 21.7%); by sub-segment, hyaluronic acid accounts for roughly 36% and botulinum toxin about 29% (Zhiyan Consulting, 2024). However, this is a "retail-end including markups" measure; the manufacturing-end market is far smaller, and starting in 2025 the industry has entered an adjustment phase of simultaneous volume and price contraction (Imeik 2025 revenue -18.9%, its first negative growth since listing; Huadong medical aesthetics -21.5%) — the growth story is being rewritten by price wars. ②GLP-1 drugs (diabetes + weight loss): This is the highest-conviction structural growth driver in Chinese pharma over the next five years. Demand base: approximately 180 million obese adults and 377 million overweight adults (National Health Commission's Report on Nutrition and Chronic Disease Status of Chinese Residents 2020 and Guidelines for Diagnosis and Treatment of Obesity 2024); current status: 2025 is the first year of China's weight-loss GLP-1 market, with Wegovy sales through regulated channels at only about RMB 900 million (ByDrug citing Novo Nordisk), implying fewer than 100,000 regulated users at an annual cost of about RMB 13,000 — penetration below 0.1%. A repricing is underway: semaglutide's core compound patent expires in China on 2026-03-20 (Supreme People's Court ruling on 2025-12-31 upheld that date), the originator has proactively cut prices (Wegovy's two presentations down 48–52%, annual cost reduced from about RMB 25,000 to RMB 13,000–16,000), and Eli Lilly's oral orforglipron priced at about USD 50/month under US Medicare signals the annual cost center of gravity in the oral era may fall another 60%+. The multiplier effect of penetration × annual cost: 1% penetration ≈ RMB 21.6 billion, 3% ≈ RMB 64.9 billion, 5% ≈ RMB 108.2 billion (2030E, 180 million people × RMB 12,000 annual cost); the neutral 3% scenario is internally consistent with L.E.K.'s "China GLP-1 market of roughly RMB 100 billion by 2030." Conclusion: this is a genuine structural inflection driven by "price × accessibility," with the demand curve shifting rightward overall — but price deflation is equally severe. Volume precedents (mazdutide's RMB 720 million in its first approval year, projected RMB 1.8 billion in its second) prove single-product breakouts are feasible, while the declining terminal price center of gravity means this is a "volume-for-price" market, not a windfall market. ③Chronic disease generics: No authoritative single market-size figure exists; under normalized centralized procurement, volumes are stable but prices decline; leading companies show single-digit growth or declines — a mature-to-declining track.
Value chain and value distribution. Across the API–formulation–distribution–end market chain, Huadong is a rare A-share player with the full "APIs–manufacturing–distribution–end market" chain: upstream (self-supplied fermentation APIs; injection-grade HA/PCL/PLLA raw materials represent a very low share of costs, and licensed manufacturers hold strong bargaining power over raw materials) → midstream (drug approvals/GMP and Class III medical aesthetics registration certificates — the value core; gross margins of licensed injectable aesthetics products generally exceed 90%, Huadong industrial gross margin 77%) → downstream (hospitals/pharmacies/e-commerce + 1,500+ private medical aesthetics institutions; Huadong Commercial covers Zhejiang distribution). Gross profit accrues mainly to the licensed manufacturing link; the distribution link (67.5% of revenue) earns only channel fees at a 7.3% gross margin. Overall downstream bargaining power is weak: prescription drugs face pricing pressure from centralized procurement and DRG, and after the supply surge in medical aesthetics products, leverage over institutions is also declining.
Supply-demand and competitive structure. Injectable medical aesthetics has shifted from supply scarcity to supply glut: from 2025-07 to 2026-06, the NMPA approved 46 Class III injectable products (25 hyaluronic acid + 12 collagen + 9 collagen-stimulating, per industry observation), PLLA biostimulators grew from 2 products in 2021 to 15, and PCL products went from exclusive to 2 — the first-mover exclusivity of Ellansé has ended, and the regenerative filler line's "sales +93% but unit price down" volume-price divergence is a microcosm of the industry. GLP-1 stands on the eve of a triple supply release: "originator price cuts + biosimilar queues + oral substitution": globally, Lilly + Novo Nordisk combined 2025 sales exceeded USD 70 billion (about 97% market share); Novo Nordisk holds roughly 83% of China's diabetes GLP-1 market; at least 10 domestic semaglutide biosimilars have filed for approval (data protection until approximately 2027-04), and orforglipron has filed in China — in 2027–2028, China's weight-loss market will see a two-layer battle of "injectable biosimilars + oral small molecules"; market access and channel positioning within the first 18 months will determine the single-product ceiling. Chronic disease generics now face entry barriers of only "API integration costs + bioequivalence consistency evaluation," with long-term supply oversupply.
Cycles and regulation. Medical aesthetics: a strong regulatory cycle is clearing the market (RF devices require Class III certificates from 2026-04, UDI traceability, new advertising rules, closure of unlicensed institutions), raising compliance costs and concentrating share toward licensed leaders — for Huadong, "short-term pain, medium-term benefit." Pharma: centralized procurement is normalized (the 11th batch of 55 drugs effective 2026-02; the 12th batch of 65 drugs opened for bidding 2026-07-31, with Huadong winning 3 and losing 4), while innovation support is strengthening (July 2025 Medical Insurance Document No. 16 + the first commercial insurance innovative drug list of 19 drugs + 114 new drugs added to the national reimbursement list) — the policy mix for Huadong is precisely "headwinds compress the existing, tailwinds fund the incremental": the commercial insurance payment channel provides a payment outlet outside the basic medical insurance for high-value weight-loss/metabolic products, a key variable for HDM1002's commercialization prospects.
Peer benchmarking (2026-10-27; Huadong data from 2025 annual report):
| Company | Revenue (RMB 100M) | Revenue Growth | Gross Margin | ROE | PE | Key Differentiation |
|---|---|---|---|---|---|---|
| Huadong Pharma | 436.12 | +4.07% | 32.36% (Industrial 77%) | 13.76% | ~13.3x | Generics-plus-innovation + distribution + medical aesthetics conglomerate; mid-transition, slowest growth, lowest valuation |
| Hengrui Pharma | 316.29 | +13.02% | N/A | 14.44% | ~39.2x | Benchmark of pure innovation (RMB 16.3 billion innovative revenue, ~30% R&D intensity); no aesthetics/distribution |
| Sino Biopharmaceutical | 318.3 | +10.3% | N/A | 7.48% (IFRS) | ~16.0x (adjusted) | Most comparable (generics-innovation hybrid); faster innovation monetization (innovative revenue RMB 12 billion+) |
| CSPC Pharmaceutical | 260.06 | -10.35% | 65.6% | 11.86% | ~19.8x | A procurement-damaged transitioning sample; core business weaker than Huadong |
| Imeik | 24.53 | -18.94% | ~94% | 16.79% | ~23.2x | Pure medical aesthetics high-margin single-product model; reflects sector-wide valuation suppression |
Company positioning within the industry: ①Chronic disease generics — defender: leading shares in acarbose, Bailing, and transplant immunology lines but continuously eroded by centralized procurement; losing 4 products in the 12th batch (31.34% of industrial revenue) confirms a downward share trend; ②Medical aesthetics — survivor of the clearing phase: retreated from challenger with Ellansé's exclusive dividend to head of the second tier (regenerative + botulinum + HA + energy-based devices remains the broadest domestic portfolio), share trending down, awaiting a new product cycle; ③GLP-1 — option holder: Yifuyan/liraglutide (first domestic weight-loss GLP-1, previous-generation molecule, low share) + semaglutide biosimilar filing + HDM1002/HDM1005 oral and dual-agonist pipeline; under neutral assumptions, 3–5% share of weight loss by 2030, corresponding to revenue of RMB 1.95–3.25 billion (≈13–22% of 2025 industrial revenue), but realization comes after 2027. Caveat: the company's claim that Yifuyan is "the first domestic GLP-1 with approvals for both diabetes and weight-loss indications" is accurate, but liraglutide is a previous-generation molecule; the medical aesthetics segment uses an "excluding intra-group eliminations" basis (RMB 1.826 billion in 2025), which differs from some research reports that simply sum Sinclair + Sinocare/Imeik China.
A generic financial framework would miss the two defining dimensions of this company — registration progress and competitive standing of licensed products/pipeline — hence this standalone chapter.
Medical aesthetics product matrix: Yiling (Ellansé, PCL biostimulator) has passed its dividend phase (domestic Sinocare/Imeik China down -31.5% in 2025); a new generation of ammunition is in place — Ruotuoxin (world's first recombinant botulinum toxin type A, approved 2026-03; differentiated recombinant route avoiding plasma/animal-source regulatory concerns, company guides for volume ramp in H2), Yiling Hengyao (next-generation biostimulator), MaiLi Precise (first domestic HA approved for the infraorbital hollow indication), V30 energy-based device (registered 2026-08) + EU MDR CE certification (2026-08) opening device exports. Verification rhythm: whether the medical aesthetics quarterly decline narrows to within -20% in 2026Q4 and turns positive in 2027 — management has given "year-by-year improvement" guidance without quantitative targets; trust the financials, not the slogans.
GLP-1/metabolic pipeline梯队 (in order of expected realization): ①Yifuyan (liraglutide 3mg, launched; first-mover but old molecule); ②semaglutide injection (under regulatory review, queued behind data protection; EAEU approval obtained; high approval probability but 10+ competitors in the same batch, collapsing unit prices); ③HDM1002 (oral small molecule; weight-loss Phase III met endpoint, NDA filing 2026Q4; diabetes Phase III data Q4; note the company's capitalized projects table lists its Phase III expected completion as 2029-12-31, a discrepancy from the market's 2027H2 approval expectation — approval timing is the core uncertainty); ④HDM1005 (GLP-1R/GIPR dual agonist; weight-loss Phase III 40-week interim analysis met primary endpoint, NDA filing 2027Q1, head-to-head 52-week data vs. tirzepatide expected year-end — data near tirzepatide levels (15%+) would trigger immediate revaluation); ⑤DR10624 (FGF21R/GCGR/GLP-1R triple agonist; MASH Phase II topline data received, to be presented at academic conferences Q4; sHTG granted CDE Breakthrough Therapy designation) — the deepest domestic metabolic pipeline in the first tier, but every asset is caught between MNC originators and domestic me-too competitors. Peak sales estimates: if HDM1002 is approved in 2027H2–2028 and captures ~4–6% of China's oral GLP-1 market, peak revenue of RMB 1.0–2.0 billion (neutral assumption vs. ~RMB 64.9 billion weight-loss market in 2030); semaglutide biosimilar contributes a peak range of RMB 2.0–3.5 billion (in a price war, closer to the lower bound). Risk-hedged watch item: HDM2005 (ROR1 ADC) granted FDA Fast Track (2026-08); out-licensing of the oncology + metabolism dual platform (company language: "flexibly considering out-licensing") is a pure unpriced option.
Overall assessment: cautiously bullish, confidence 0.58, time horizon 6–12 months. The company's quality is above average (ROE 14%, net cash RMB 3.45 billion, high cash flow quality, 47.8% payout ratio), the price sits in a historically extreme discount zone (10-year low PB, implied perpetual growth 1.5–1.7%), with a base-case fair value of RMB 27.5–30.4 and probability-weighted expected price of about RMB 29.2 (+11.7%) — moderately positive odds. Strategically this is a "left-side accumulation, wait for verification" setup: the 2026Q4 quarterly report, HDM1002 NDA acceptance, and provincial procurement implementation documents constitute a two-way verification window; we do not recommend a heavy one-directional bet before implementation details land. Core constraints: the 2027 earnings downgrade has not fully played out (our 2027E is ~11% below consensus), the medical aesthetics inflection has only qualitative guidance, and the jump in R&D capitalization ratio means the "quality discount" of reported profits requires ongoing adjustment.
Risk and catalyst alerts (see tracking list for details): downside — in-hospital procurement losses exceeding 55%, indobufen patent invalidated, 2026 annual report goodwill + development cost impairment exceeding RMB 500 million, HDM1002 approval delayed beyond 2028, premature oral GLP-1 price war; upside — patent litigation victory + better-than-expected out-of-hospital conversion, medical aesthetics decline narrowing to within -20%, strong HDM1005 head-to-head data, out-licensing of metabolic/oncology pipeline, buyback program implementation. Touching RMB 27.5 (lower bound of base range) confirms the start of recovery; touching RMB 30.4 (upper bound) means margin of safety is exhausted and triggers a realization/reduction assessment zone; a break below RMB 19.4 (bear-case floor) requires rebuilding the valuation framework.
This report's price anchors are frozen at the 2026-10-27 closing price of RMB 26.15; financial data are as of the 2026 interim report (balance sheet stock as of 2026-06-30). This report was generated by Loyan AI and is for research reference only; it does not constitute investment advice.